Fertility and Sterility
Volume 93, Issue 1 , Pages 239-250 , 1 January 2010

Gene therapy targeting leiomyoma: adenovirus-mediated delivery of dominant-negative estrogen receptor gene shrinks uterine tumors in Eker rat model

  • Memy H. Hassan, M.Sc.

      Affiliations

    • Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas
    • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
    • ,
  • Salama A. Salama, Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas
    • ,
  • Dong Zhang, Ph.D.

      Affiliations

    • Department of Carcinogenesis, M. D. Anderson Cancer Center, University of Texas, Texas
    • Center for Women Health Research, Department of Obstetrics and Gynecology, Meharry Medical College, Nashville, Tennessee
    • ,
  • Hossam M.M. Arafa, Ph.D.

      Affiliations

    • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
    • ,
  • Farid M.A. Hamada, Ph.D.

      Affiliations

    • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
    • ,
  • Hala Fouad, M.D., Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas
    • ,
  • Cheryl C. Walker, Ph.D.

      Affiliations

    • Department of Carcinogenesis, M. D. Anderson Cancer Center, University of Texas, Texas
    • ,
  • Ayman Al-Hendy, M.D., Ph.D.

      Affiliations

    • Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, Texas
    • Center for Women Health Research, Department of Obstetrics and Gynecology, Meharry Medical College, Nashville, Tennessee
    • Corresponding Author InformationReprint requests: Ayman Al-Hendy, Professor and Vice Chair, Center for Women Health Research, Department of Obstetrics and Gynecology, Meharry Medical College, 1005 Dr. D. B. Todd Jr. Blvd., Nashville, Tennessee 37208 (FAX: 615-963-3125).

Received 6 September 2008 ,Revised 23 September 2008 ,Accepted 30 September 2008.

References 

  1. Maruo T, Matsuo H, Samoto T, Shimomura Y, Kurachi O, Gao Z, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids. 2000;65:585–592
  2. Walker CL, Burroughs KD, Davis B, Sowell K, Everitt JI, Fuchs-Young R. Preclinical evidence for therapeutic efficacy of selective estrogen receptor modulators for uterine leiomyoma. J Soc Gynecol Invest. 2000;7:249–256
  3. Stewart EA. Uterine fibroids. Lancet. 2001;357(9252):293–298
  4. Farhi J, Ashkenazi J, Feldberg D, Dicker D, Orvieto R, Ben Rafael Z. Effect of uterine leiomyomata on the results of in-vitro fertilization treatment. Hum Reprod. 1995;10:2576–2578
  5. Eldar-Geva T, Meagher S, Healy DL, MacLachlan V, Breheny S, Wood C, et al. Effect of intramural, subserosal, and submucosal uterine fibroids on the outcome of assisted reproductive technology treatment. Fertil Steril. 1998;70:687–691
  6. Surrey ES, Lietz AK, Schoolcraft WB. Impact of intramural leiomyomata in patients with a normal endometrial cavity on in vitro fertilization–embryo transfer cycle outcome. Fertil Steril. 2001;75:405–410
  7. Hart R, Khalaf Y, Yeong CT, Seed P, Taylor A, Braude P. A prospective controlled study of the effect of intramural uterine fibroids on the outcome of assisted conception. Hum Reprod. 2001;16:2411–2417
  8. Rein MS, Barbieri RL, Friedman AJ. Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol. 1995;172:14–18
  9. Coddington CC, Collins RL, Shawker Th, Anderson R, Loriaux DL, Winkel CA. Long-acting gonadotropin hormone-releasing hormone analog used to treat uteri. Fertil Steril. 1986;45:624–629
  10. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstetric Gynecology. 1989;160:637–641
  11. Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update. 1996;4:295–296
  12. Chegini N, Verala J, Luo X, Xu J, Williams RS. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Investig. 2003;10:161–171
  13. Sozen I, Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril. 2002;78:1–12
  14. Al-Hendy A, Lee EJ, Wang HQ, Copland JA. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol. 2004;191:1621–1631
  15. Parazzini F, Negri E, La Vecchia C, Chatenoud L, Ricci E, Guarnerio P. Reproductive factors and risk of uterine fibroids. Epidemiology. 1996;7:440–442
  16. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ. 1986;293:359–362
  17. Benassayag C, Leroy MJ, Rigourd V, Robert B, Honore JC, Mignot TM, et al. Estrogen receptors (ERalpha/ERbeta) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma. Am J Physiol. 1999;276:E1112–E1118
  18. Wang Y. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol. 2002;146:447–456
  19. Al-Hendy A, Salama SA. Ethnic distribution of estrogen receptor-alpha polymorphism is associated with a higher prevalence of uterine leiomyomas in black Americans. Fertil Steril. 2006;86:686–693
  20. Brandon DD, Bethea CL, Strawn EY, Novy MJ, Burry KA, Harrington MS, et al. Progesterone receptor messenger ribonucleic acid and protein are over expressed in human uterine leiomyomas. Am J Obstet Gynecol. 1993;169:78–85
  21. Brandon DD, Erickson TE, Keenan EJ, Strawn EY, Novy MJ, Burry KA, et al. Estrogen receptor gene expression in human uterine leiomyomata. J Clin Endocrinol Metab. 1995;80:1876–1881
  22. Thorp JM, Katz VL. Submucous myomas treated with gonadotropin releasing hormone agonist and resulting in vaginal hemorrhage. A case report. J Reprod Med. 1991;36:625–626
  23. Vilos GA. Treatment options for uterine fibroids. [abstract] Can J Diag. 2000;17:55–59
  24. Walker CL, Stewart EA. Uterine fibroids: the elephant in the room. Science. 2005;308:1589–1592
  25. Bachmann G. Expanding treatment options for women with symptomatic uterine leiomyomas: timely medical breakthroughs. Fertil Steril. 2006;85:46–47
  26. Lefebvre G, Allaire C, Jeffrey J, Vilos GA, Arneja J, Birch C, et al. Society of Obstetricians and Gynecologists of Canada [SOGC] Clinical Practice Gynecology Committee and Executive Committee and Council. SOGC clinical guidelines. Hysterectomy. J Obstet Gynecol Can. 2002;24:37–76
  27. VeKaut BS. Changing trends in treatment of leiomyomata uteri. [abstract] Curr Opin Obstet Gynecol. 1993;5:301
  28. Al Hendy A, Salama A. Gene therapy and uterine leiomyoma: a review. Hum Reprod Update. 2006;16:385–400
  29. Vercellini P, Maddalena S, De Giorgi O, Aimi G, Crosignani PG. Abdominal myomectomy for infertility: a comprehensive review. Hum Reprod. 1998;13:873–879
  30. Vilos GA, Daly LJ, Tse BM. Pregnancy outcome after laparoscopic electromyolysis. J Am Assoc Gynecol Laparosc. 1998;5:289–292
  31. Payne JF, Haney AF. Serious complications of uterine artery embolization for conservative treatment of fibroids. Fertil Steril. 2003;79:128–131
  32. Andrei JL, Marshall LA, Domestic DA, Jaffe RB. Therapeutic uses of gonadotropin-releasing hormone analogs. Obstet Gynecol Surv. 1987;42:1–21
  33. Eisinger SH, Meldrum S, Fiscella K, Le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101:243–250
  34. Ince BA, Zhuang Y Wrenn CK, Shapiro DJ, Katzenellenbogen BS. Powerful dominant negative mutants of the human estrogen receptor. J Biol Chem. 1993;268:14026–14032
  35. Houston KD, Hunter DS, Hodges LC, Walker CL. Uterine leiomyomas: mechanisms of tumorigenesis. Toxicol Pathol. 2001;29:100–104
  36. Cook JD, Walker CL. The Eker rat: establishing a genetic paradigm linking renal cell carcinoma and uterine leiomyoma. Curr Mol Med. 2004;4:813–824
  37. Everitt JI, Wolf DC, Howe SR, Goldsworthy TL, Walker CL. Rodent model of reproductive tract leiomyomata. Clinical and pathological features. Am J Pathol. 1995;146:1556–1567
  38. Lee EJ, Duan WR, Jakacka M, Gehm BD, Jameson JL. Dominant negative ER induces apoptosis in GH (4) pituitary lactotrope cells and inhibits tumor growth in nude mice. Endocrinol. 2001;142:3756–3763
  39. Al-Hendy A, Magliocco AM, Al Tweigeri T, Braileanu G, Crellin N, Li H, et al. Ovarian cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am J Obstet Gynecol. 2000;182:553–559
  40. Boyd W. A text book of pathology, structure and function in disease. Philadelphia: Lea and Febiger; 1979;
  41. Yamada I, Tsunoda A, Noguchi Y, Komatsuzaki A, Shibuya H. Tumor volume measurements of acoustic neuromas with three-dimensional constructive interference in steady state and conventional spin-echo MR imaging. Magn Reson Imag. 2000;12:826–832
  42. Quast MJ, Neumeister H, Ezell EL, Budelmann BU. MR microscopy of cobalt-labeled nerve cells and pathways in an invertebrate brain (Sepia officinalis, Cephalopoda). Magn Reson Med. 2001;45:575–579
  43. Willis WD, Al Chaer ED, Quast MJ, Westlund KN. A visceral pain pathway in the dorsal column of the spinal cord. Proc Natl Acad Sci U S A. 1999;96:7675–7679
  44. Al-Hendy A, Auersperg N. Applying the herpes simplex virus thymidine kinase/ganciclovir approach to ovarian cancer: an effective in vitro drug-sensitization system. Gynecol Obstet Invest. 1997;43:268–275
  45. Colgan TJ, Pendergast S, Leblanc M. The histopathology of uterine leiomyomas following treatment with gonadotropin-releasing hormone analogs. Hum Pathol. 1994;24:1073–1077
  46. Salama S, Kamel M, Christman G, Wang H, Al-Hendy A. Gene therapy of uterine fibroids: adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir treatment inhibits growth of human and rat leiomyoma cells. Gynecol Obstet Invest. 2007;63:61–70
  47. Burroughs KD, Fuchs-Young R, Davis B, Walker CL. Altered hormonal responsiveness of proliferation and apoptosis during myometrial maturation and the development of uterine leiomyomas in the rat. Biol Reprod. 2000;63:1322–1330
  48. Hassan MH, Salama SA, Arafa HM, Hamada FM, Al-Hendy A. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene in uterine leiomyoma cells abrogates estrogen- and progesterone-regulated gene expression. J Clin Endocrinol Metab. 2007;92:3949–3957
  49. Salama SA, Jamaluddin M, Kumar R, Hassan MH, Al-Hendy A. Progesterone regulates catechol-O-methyl transferase gene expression in breast cancer cells: distinct effect of progesterone receptor isoforms. J Steroid Biochem Mol Biol. 2007;107:253–261
  50. Pfaffl MW. A new mathematical model for relative quantifications in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45
  51. Othman ER, Salama SA, Ismail N, Al-Hendy A. Gene therapy of endometriosis: adenovirus mediated expression of dominant negative estrogen receptor induces apoptosis in human endometriotic cells. Fertil Steril. 2007;88:462–471
  52. Sbrana E, Mateo RI, Xiao SY, Popov VL, Newman PC, Tesh RB. Clinical laboratory, virologic, and pathologic changes in hamsters experimentally infected with pirital virus (Arenaviridae): a rodent model of Lassa fever. Am J Trop Med Hyg. 2006;74:1096–1102
  53. Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat WR, et al. A cancer gene therapy approach utilizing an antierbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial. Clin Cancer Res. 2000;6:3081–3087
  54. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ, Zamarron C, et al. Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries: potential for immunosuppression and vector engineering to overcome barriers of immunity. J Clin Invest. 1997;99:209–219
  55. Smith TAG, Mehaffey MG, Kayda DB, Saunders JM, Yei S, Trapnell BC, et al. Adenovirus-mediated expression of therapeutic plasma levels of human factor-IX in mice. Nat Genet. 1993;5:397–02
  56. Harvey BG, Hackett NR, El-Sawy T, Rosengart TK, Hirschowitz EA, Lieberman MD, et al. Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs. J Virol. 1999;73:6729–6742
  57. Murphy LJ, Ghahary A. Uterine insulin-like growth factor-1: regulation of expression and its role in estrogen-induced uterine proliferation. Endocr Rev. 1990;11:443–453
  58. Chegini N, Verala J, X. Luo X, Xu J, Williams RS. Gene expression profile of leiomyoma and myometrium and the effect of gonadotropin releasing hormone analogue therapy. J Soc Gynecol Invest. 2003;10:161–171
  59. Lazennec G, Alcorn JL, Katzenellenbogen BS. Adenovirus-mediated delivery of a dominant negative estrogen receptor gene abrogates estrogen-stimulated gene expression and breast cancer cell proliferation. Mol Endocrinol. 1999;13:969–980
  60. Dixon D, Flake GP, Moore AB, He H, Haseman JK, Risinger JI, et al Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch. 2002;441:53–62
  61. Gao Z, Matsuo H, Satoshi N, Kurachi O, Maruo T. p53 tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17B-estradiol. J Clin Endocrinol Metab. 2002;87:3915–3920
  62. Imai A, Takagi A, Horibe S, Takagi H, Tamaya T. Evidence for tight coupling of gonadotropin-releasing hormone receptor to stimulated fas ligand expression in reproductive tract tumors: possible mechanism for hormonal control of apoptotic cell death. J Clin Endocrinol Metab. 1998;83:427–431
  63. Bargonetti J, Manfredi JJ. Multiple roles of the tumor suppressor p53. Curr Opin Oncol. 2002;14:86–91
  64. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis—the p53 network. J Cell Sci. 2003;116:4077–4085
  65. Lane DP. Cancer—p53, guardian of the genome. Nature. 1992;358(6381):15–16
  66. Nagata S. Apoptosis by death factor. Cell. 1997;88:355–365
  67. Krammer PH. CD95's deadly mission in the immune system. Nature. 2000;407(6805):789–795
  68. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science. 1997;275(5303):1129–1132
  69. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9–dependent manner. J Cell Biol. 1999;144:281–292
  70. Van der Meer IM, Oei HH, Hofman A, Pols HA, de Jong FH, Witteman JC. Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis—the Rotterdam Coronary Calcification Study. Atherosclerosis. 2006;189:464–469
  71. Chang HY, Nishitoh H, Yang X, Ichijo H, Baltimore D. Activation of apoptosis signal regulating kinase 1 (Ask1) by the adapter protein Daxx. Science. 1998;281(5384):1860–1863
  72. Cecconi F. Apaf1 and the apoptotic machinery. Cell Death Diff. 1999;6:1087–1098
  73. Matsuda K, Yoshida K, Taya Y, Nakamura K, Nakamura Y, Arakawa H. p53AIP1 regulates the mitochondrial apoptotic pathway. Cancer Res. 2002;62:2883–2889
  74. Chiou SK, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol. 1994;14:2556–2563
  75. Reed JC, Jurgensmeier JM, Matsuyama S. Bcl-2 family proteins and mitochondria. Biochim Biophys Acta. 1998;1366:127–137
  76. Nomura M, Shimizu S, Ito T, Narita M, Matsuda H, Tsujimoto Y. Apoptotic cytosol facilitates Bax translocation to mitochondria that involves cytosolic factor regulated by Bcl-2. Cancer Res. 1999;59:5542–5548
  77. Wu , Blanck A, Olovsson M, Henriksen R, Lindblom B. Expression of Bcl-2, Bcl-x, Mcl-1, Bax and Bak in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause. J Steroid Biochem Mol Biol. 2002;80:77–83
  78. Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ. Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 1999;44:487–492
  79. Loy CJ, Evelyn S, Lim FK, Liu MH, Yong EL. Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-gamma ligand, pioglitazone. Mol Hum Reprod. 2005;11:561–566
  80. Kurki P, Vanderlaan M, Dolbeare F, Gray J, Tan EM. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res. 1986;166:209–219
  81. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7:812–821
  82. Ingman WV, Robertson SA. Defining the actions of transforming growth factor beta in reproduction. Bioessays. 2002;24:904–1429
  83. Ignotz RA, Massague J. Transforming growth-factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular-matrix. J Biol Chem. 1986;261:4337–4529
  84. Ignotz RA, Endo T, Massague J. Regulation of fibronectin and type-I collagen messenger-RNA levels by transforming growth-factor-beta. J Biol Chem. 1987;262:6443–6629
  85. Hallenbeck PL, Stevenson SC. Targetable gene delivery vectors. Adv Exp Med Biol. 2000;465:37–46
  86. Worgall S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther. 1997;8:37–44
  87. Roth DA, McKirnan MD, Canestrelli I, Gao MH, Dalton N, Lai NC, et al. Intracoronary delivery of an adenovirus encoding fibroblast growth factor-4 in myocardial ischemia: effect of serum antibodies and previous exposure to adenovirus. Hum Gene Ther. 2006;17:230–238
  88. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995;69:2004–2015
  89. Harvey BG, Hackett NR, Ely S, Crystal RG. Host responses and persistence of vector genome following intrabronchial administration of an E1 (−) E3 (−) adenovirus gene transfer vector to normal individuals. Mol Ther. 2001;3:206–215
  90. Blake RE. Leiomyomata uteri: hormonal and molecular determinants of growth. J Natl Med Assoc. 2007;99:1170–1184
  91. Rocconi RP, Zhu ZB, Stoff-Khalili M, Rivera AA, Lu B, Wang M, et al. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd)1. Gynecol Oncol. 2007;105:113–121
  92. Sullivan DM, Jensen TG, Taichman LB, Csaky KG. Ornithine-delta-aminotransferase expression and ornithine metabolism in cultured epidermal keratinocytes: toward metabolic sink therapy for gyrate atrophy1. Gene Ther. 1997;4:1036–1044
  93. Hassan MH, Khatoon N, Curiel DT, Hamada FM, Arafa HM, Al-Hendy A. Toward gene therapy of uterine fibroids: targeting modified adenovirus to human leiomyoma cells. Hum Reprod. 2008;23:514–524

 M.H. has nothing to disclose. S.S. has nothing to disclose. D.Z. has nothing to disclose. H.A. has nothing to disclose. F.H. has nothing to disclose. H.F. has nothing to disclose. C.W. has nothing to disclose. A.A.-H. has nothing to disclose.

 Supported by National Institutes of Health/National Institute of Child Health and Human Development grant no. R01 HD046228-01.

PII: S0015-0282(08)04127-7

doi: 10.1016/j.fertnstert.2008.09.086

Fertility and Sterility
Volume 93, Issue 1 , Pages 239-250 , 1 January 2010

Article Tools

* Image Usage & Resolution